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Polycyclic and halogenated aromatic hydrocarbons (PAHs and HAHs)
are widespread and persistent environmental contaminants. Most of their
toxicological effects are mediated through activation of the aryl hydrocarbon
receptor (AhR), which leads to transcriptional activation of cytochrome P-450
lA l and 1A2 (CYP lA l/2) genes. Induction of CYP lA l/2 increases drug
metabolism and enhances the generation of reactive oxygen species (ROS) in
vivo. Oxidative stress is an important mediator of various neurological and
hepatic disorders. In the brain, oxidative damage can alter key components
of glutamate homeostasis, such as glutamine synthetase (GS). This change
can generate abnormally elevated extracellular glutamate, and lead to
excitotoxicity.
PAHs and HAHs have been shown to induce CYP lA l in rat brain.
However, whether the induction of CYP lA l can cause oxidative damage or
interact with other pathologies in the central nervous system has not been
reported.
In the present study, we investigated the effect of CYP lA l induction
on oxidative status in the brain and liver. We demonstrated that induction of
CYP lA l by 3-methylcholanthrene (3-MC) did not oxidize proteins or lipids,
or decrease GS activity in rat brain and liver. Furthermore, the induction of
CYP lA l in the brain and liver did not enhance the extent of lipid
peroxidation in either tissue following oxidative challenge. If increased CYP
lA l activity in the brain and liver following 3-MC treatment leads to
increased ROS formation, the increase is insufficient to overwhelm the
endogenous antioxidant defense system, produce detectable oxidative
damage, and alter glutamate homeostasis.
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Abbreviations
AhR: aryl hydrocarbon receptor
AhREs: aryl hydrocarbon-response elements
A rnt: aryl hydrocarbon receptor nuclear translocator
CNS: central nervous system
CYP: cytochrome P-450
CYP lA l: cytochrome P-450 lA l
CYP 1A2: cytochrome P-450 1A2
CYP 2E1: cytochrome P-450 2E1
EROD: ethoxyresorufin O-deethylase
GS: glutamine synthetase
GSH: glutathione
GST : glutathione S-transferase
HAHs: halogenated aromatic hydrocarbons
H 2 O 2 : hydrogen peroxide
Hsp90: heat shock protein 90
3-MC: 3-methylchoianthrene
a-N F: a-naphthoflavone, CYP lA l inhibitor
P-NF: P-naphthoflavone, CYP lA l inducer
O 2 : superoxide anion
O H : hydroxyl radical
PAHs: polycyclic aromatic hydrocarbons
ROS: reactive oxygen species
TEARS: thiobarbitunc acid-reactive substance
TCDD: 2, 3, 7, 8-tetrachloro dibenzo-p-dioxin
UDP-GT : UDP glucuronosyltransferase
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Introduction:
Polycyclic and Halogenated Aromatic Hydrocarbons:
Polycyclic aromatic hydrocarbons (PAHs) and halogenated aromatic
hydrocarbons (HAHs) are widely distributed environmental toxins. Major
sources of PAH exposure include cigarette smoke, smoked food products,
and air pollution (Costa, 1998). The HAH family includes polychlorinated
dibenzo-p-dioxins (PCDDs), polychlorinated dibenzofurans (PCDFs) and
polychlorinated biphenyls (PCBs). HAHs are mainly industrial contaminants.
PCBs are used in heat transfer fluid. PCDDs and PCDFs are byproducts in
the synthesis of PCB, phenoxyherbicides, and chlorinated phenols. PCDDs
are also produced by paper mills, forest fires, and automobile exhaust (Costa,
1998).
In spite of wide exposure, the levels of PAHs in body tissues are
normally unmeasurable (Wolff, et.al., 1996). PAHs are typically short lived
in the body and are metabolized by several cytochrome P-450s (CYPs) to
electrophilic derivatives. The principle enzymes involved in PAH metabolism
are the lA l and 1A2 subtypes of cytochrome P-450 (CYP lA l/2).
Cytochrome P-450 2B1 (CYP 2B1) also plays a role in PAH metabolism
(Hankinson, 1995). In contrast, HAHs are relatively resistant to metabolism
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and more likely to build up in liver and adipose tissue upon exposure
(Hankinson, 1995; Abraham, et.al., 1988). The apparent half life for 2, 3, 7,
8-tetrachloro dibenzo-p-dioxin (TCDD) is up to several weeks in rodents
(Rose, et.al., 1976), and is even longer in primates (Krowke, 1986; Poiger
and Schlater, 1986).
Most of the toxic effects for PAHs and HAHs are caused by activation
of the aryl hydrocarbon receptor (AhR) (Hankinson, 1995; Dogra, et.al.,
1998). Both PAHs and HAHs can transcriptionally induce biotransforming
phase I and conjugating phase II metabolic enzymes (Hankinson, 1995;
Poellinger, 1995). The induction of these enzymes significantly changes the
metabolism for exogenous drugs and toxicants (Pitot HI, 1995; Parkinson,
1995). The attack of the electrophilic metabolites of PAHs on DNA leads to
mutation and tumor formation. Long term exposure of PAHs and HAHs have
been reported to cause sarcoma, hepatic cancer, and breast cancer in rodents
(Pitot ni, 1995; Kociba, 1982). In addition, toxicities for PAHs and HAHs
also include reproductive problems (Tomas, 1995; Brouwer, et.al., 1995),
endocrine dysfunction (Capen, 1995), developmental retardation (Brouwer,
et.al., 1995), and cardiovascular pathology (Ramos, et.al., 1995). A
considerable body of research in the last fifteen years has established specific
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biological cascades involved in the effects of PAHs and HAHs. PAHs and
HAHs alter intracellular Ca^^ homeostasis (Costa, 1998), transcriptionally
induce specific genes through the Aryl hydrocarbon receptor (AhR) (Nobert
and Gonzalez, 1987; Quattrochi, 1989; Landers, 1991), and induce other
genes not associated with AhR (Okey, et.al., 1994).
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Figure 1. Basic scheme for the transcriptional activation o f CYP lA l/2 genes by PAHs
and HAHs. TCDD, tetrachloro dibenzo-p-dioxin; MC, 3- methylcholanthrene; AhR, aryl
hydrocarbon receptor; Arnt, AhR nuclear translocator protein; AhREs, aryl hydrocarbon
receptor-responsive element; lA l, CYP lA l; 1A2, CYP 1A2. (Okey, et.al, 1994)

PAHs and HAHs bind to a cytosolic protein, AhR, when they enter into
the cells. Latent AhR is complexed with heat shock protein 90 (Hsp90).
Following binding, AhR is activated and the complex is transported into the
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Following binding, AhR is activated and the complex is transported into the
nucleus. Hsp90 is then released from the complex and the transformed
complex dimerizes with the aryl hydrocarbon nuclear translocator (Amt).
The AhR-Amt heterodimer binds to specific DNA sequences, known as the
aryl hydrocarbon-response elements (AhREs), and induces the transcription
of numerous metabolic enzymes, cytokines and growth factors (Okey, et.al.,
1994). The AhRE sequence, located upstream from the activated gene,
functions as an enhancer region (Dogra, et.al., 1998). Genes encoding both
phase I and phase II enzymes can be transcriptionally induced by PAHs
through this AhR-dependent mechanism. These genes include the phase I
enzymes CYP 1A l/2 and aldehyde dehydrogenase (ALDH), and the phase II
enzyme glutathione S-transferase (GST) (Okey, et.al., 1994).
TCDD, 3-Methylcholanthrene (3-MC), and p-naphthoflavone (P-NF)
are potent CYP 1A1 inducers. These compounds can induce CYP 1A1 in the
liver and also extrahepatic tissues (Juchau, et.al., 1979; Schilter and
Omiecinski, 1994; Unkila, et.al., 1993). For example, 3-MC (5 injections of
110 pmol/Kg) induces CYP 1A1 in both neurons and glial cells one day after
treatment (Dhawan, A., 1990).
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Cytochrome P-450:
Cytochrome P-450 (CYP) is a group of NADPH-dependent, oxidative
enzymes capable of metabolizing a number of xenobiotics and endogenous
compounds (Gonzalez, 1991). All CYPs are hemoproteins with a cysteinethiolate ligand binding to heme iron (Gonzalez, 1991). CYPs can be
classified in two general classes based on their means for obtaining electrons
from NADPH and, in addition, their intracellular location in eukaryotes
(Gonzalez, 1991). Mitochondrial CYPs, such as CYP llA (side-chain
cleavage cytochrome P-450) and CYP 17, are found exclusively in the inner
mitochondrial membrane and are involved in steroid biosynthesis. They
receive electrons via an iron-sulfur protein from flavin adenine dinucleotide
(FAD)-containing enzyme (Gonzalez, 1991). The second class of CYPs is
bound to microsomal membranes, and mainly involved in metabolism of
foreign compounds. These microsomal CYPs obtain electrons via NADPHcytochrome P-450 reductase, and cytochrome bs (Gonzalez, 1991). The
microsomal CYPs are divided into the four gene families: CYP 1, 2, 3, and 4.
All CYPs within a single gene family exhibit greater than 40% sequence
homology, and CYPs within the same subfamily have more than 55% identity
in sequences (Gonzalez, 1991). CYPs catalyze one-electron delivery
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oxidative reactions in vivo and in vitro, such as carbon hydroxylation,
heteroatom release reactions, and oxidation of unsaturated bonds
(Guengerich, 1991).
Multiple cytochrome P450 isozymes have been purified and
characterized in different tissues in rodents and mammals. The earliest work
was conducted on hepatic enzymes, due to the relatively high concentration
of CYP and the significance of the liver in metabolism of various drugs and
cholesterol. The expression, function, and regulation of isoforms of CYP
differ among species. Human liver microsomes contain relatively high levels
of CYP 1A2, but not CYP 1A1. In contrast to CYP 1A l, CYP 1A2 is not
expressed in extrahepatic tissues (Parkinson, 1995). The most abundant
CYP in mammalian and rodent liver is the CYP 3A gene family. CYPs 2A,
2C, 2D, 2E1, and 4A are also constitutively expressed in their liver
(Gonzalez, 1991; Funae and Imaoka, 1991). The hepatic CYPs biotransform
a wide range of xenobiotics and endogenous compounds (Parkinson, 1995).
The expression and activity of different isoforms of CYP in the liver are
regulated by numerous compounds (Parkinson, 1995; Dogra, et.al., 1998).
For example, ethanol is a potent CYP 2E1 inducer, while PAHs and HAHs
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markedly induce CYP lA l in the liver. Inhibition or induction of CYPs
affects the rate of xenobiotic transformation (Parkinson, 1995).
CYP enzymes have been detected in the brain. In untreated rats, the
brain microsomal CYP concentration is approximately 1%-3% of that found
in the liver (Warner, et.al., 1988). The amount of CYP is unevenly
distributed among brain regions. Major isoforms of hepatic CYP, such as
CYP 3A2, 2C11, and 2A1, are either undetectable or only account for a small
fraction of brain CYP (Warner, et.al., 1991). CYP lA l/2, 2B1, 3A1, and
2E1 are the main subtypes of CYP detected in the brain by
immunohistochemical studies, western blotting, and RT-PCR (Warner, et.al.,
1991; Schilter and Omiecinski, 1994). CYP lA l/2 have been detected in
both neurons and glial cells (Kohler, et.al., 1988). CYP lA l/2 mRNA and
enzyme are present in the striatum, hypothalamus, olfactory bulbs, and, to a
lesser extent, in other regions of the brain (Kohler, et.al., 1988; Scholter and
Omiecinski, 1994). In contrast to the liver, exposure to the well-known
hepatic CYP inducers, including PAHs, ethanol, and barbiturates, produces
no more than a 150% increases in CYP activity in the rat brain, while liver
CYP activity increases by an order of magnitude (Rouet, et.al, 1981;
Srivastava, et.al, 1983).
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In spite of relatively low concentrations in the brain, CYPs have very
important physiological functions and toxicological consequences in the
central nervous system (CNS). Brain CYPs metabolize drugs entering into
brain, regulate intracellular cholesterol levels, activate signal transduction via
the formation of arachidonic acid, and regulate vascular tone (Warner, et.al.,
1991). In addition, CYPs produce cytotoxic metabolites from industrial
solvents and aromatic hydrocarbons in the brain. For example, bis
(chloromethyl) ether, and acrylonitrile can cause glioma via a CYP 2E1
metabolite in experimental animals (Hopwell and Wright, et.al., 1969;
Maltony, et.al., 1982). After ethanol treatment, increased generation of
oxygen radicals in rat brain and astrocyte cultures can be partially inhibited
by an antibody against CYP 2E1 (Bondy and Guo, 1994; Montoliu, 1995).
The CYP catalytic cycle involves the binding of the enzymes to
substrate, followed by binding of molecular oxygen to the heme in CYP,
activation of the complex to a reactive intermediate, and release of
hydroxylated substrate (Park, et.al., 1996). Autooxidation of the cytochrome
P-450 complex produces superoxide (Kappus, 1991). The dismutation of
superoxide anion leads to the formation of hydrogen peroxide. OH , the most
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reactive oxygen radical, is produced by Fenton’s reaction when hydrogen
peroxide reacts with reduced metalloproteins (Kappus, 1991).
Induction of CYPs by various substances enhances ROS generation in
vivo and in vitro. The well known example is ethanol-induced oxidative
stress in liver. After ethanol administration, an increase in ROS level and
increase in lipid peroxidation occur. These effects can be effectively
inhibited by antibody against CYP 2E1 (Higuchi, et.al., 1996; Lieber, 1997).
Induction of CYP 1A l by TCDD has been reported to cause oxidative DNA
damage in hepatoma cells. The increased generation of 8-oxo-2’deoxyguanosine, a biomarker of oxidative DNA damage, can be reduced by a
CYP lA l inhibitor (Park, et.al., 1996).
Reactive Oxygen Species and Oxidative Stress;
Various kinds of neurological disorders and hepatic injuries involve
oxidative stress. These include stroke, Alzheimer’s disease, Amyotrophic
Lateral Sclerosis, Parkinson Disease, liver fibrogenesis, and alcoholic liver
(Wilson, 1997; Markesbery, 1997; Jenner and Olanow, 1996; Liu, 1996;
Lieber, 1997). In addition, oxidative stress plays a role in various ageassociated diseases, including atherosclerosis, neoplastic diseases, diabetes,
and chronic inflammatory diseases (Stohs, 1995).
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Reactive oxygen species (ROS) are generated as intermediates during
the reduction of oxygen to water. ROS include superoxide anion (O 2 ' ),
hydrogen peroxide (H 2 O 2 ), hydroxyl radical (OH ), singlet oxygen (^0 2 ) and
peroxynitrite (ONOO ■) (Junod, 1986; Powis, 1989). Unpaired electrons in
the outer shell make ROS very unstable. They can react with other molecules
to gain or lose electrons (Downey, 1990). ROS are capable of oxidizing
proteins, lipids, and nucleic acids. Oxidation of proteins leads to changes in
enzyme activity, and often leads to more rapid degradation of the respective
protein (Stadtman, 1992). Lipid peroxidation damages cell membrane as well
as extracellular lipids, and disrupts cellular homeostasis (Kappus, 1991).
Oxidation of nucleic acids leads to strand breaks and hydroxylated
nucleosides. Misrepair of the DNA lesion results in mutagenicity and even
carcinogenesis (Halliwell, et.al., 1991). Therefore, the consequences of ROS
exposure include altered gene regulation and signal transduction, apoptosis,
necrosis, fibrosis, and carcinogenesis (Kaplowitz and Tsukamoto, 1996).

10
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

ETOH

TNF

r*r.

tnftammaiion
(phagoeyne eailsk

I
4

/

miteehendna
(ubiaemiauinona»

PASO (2£1)
I OSHm
Redox eycung drugs
(gutnonest

iL-a
O xidasM

(xantnina. aldanvcw.
tatty acidt

Fe’’^, Cu** ovsnoed

Lpo-a

Tranacnptidn
laetors
(e.g. NF-*8t

Protein
DNA

{ GENE

r e g u l a t io n }
{ APOPTOSIS }
- Cytoktnee
• AdtMsion tnoteeuiaa
• Acuta pdaaa and oxidant reaoonaa genes
• Ftbroats 7

NECROSIS
FIBROSIS
CANCER

}

Figure 2. Schematic outline for the source o f oxidative stress and consequences o f ROS
exposure. P450 (2E1), CYP 2E1; O2 , superoxide anion; OH, hydroxyl radical; H 2 O 2 ,
hydrogen peroxide; GSHm, mitochondrial GSH; TNF, tumor necrosis factor; LPO, lipid
peroxidation.

(Kaplowitz and Tsukamoto, 1996)

In most circumstances, ROS can be effectively scavenged by
endogenous enzymatic and non-enzymatic anti oxidants (Machlin and
Bendich., 1987; Sies, 1997). However, in pathological situations, the
generation of ROS overwhelms the antioxidant defense (Sies, 1997). The
extent of tissue damage is the result of the imbalance between the free
radicals generated and the antioxidant defense system (Machlin and Bendich,
1987; Stohs, 1995).
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Defenses against ROS include enzymes, proteins, and radical
scavengers. The enzymes superoxide dismutase (SOD), catalase, and
glutathione peroxidase minimize exposure to ROS by converting O 2 *and
H 2 O 2 to water (Halliwell, 1995). Auxiliary enzymes, including glutathione
reductase, y-glutamylcysteine synthetase, GSH synthetase, and glucose-6—
phosphate dehydrogenase, contribute to the antioxidant defense through GSH
and NADPH biosynthesis or regeneration (Kaplowitz, et.al., 1996).
Tocopherol, ascorbic acid (reduced), beta-carotene, glutathione, bilirubin, and
transferrin effectively scavenge ROS and terminate free radical reactions
(Junod, 1986; Machlin and Bendich., 1987; Kaplowitz, et.al., 1996).
CYPs are an important generator of ROS (Sies, 1997). In addition to
CYPs, there are several important sources for the generation of ROS.
Electron outflow from mitochondria (Freeman and Crapo, 1982; Richter,
1995), metal accumulation (Kaplowitz and Tsukamoto, 1996), activation of
nitric oxide synthetase (Bredt and Snyder, 1989), activation of arachidonic
acid metabolism (Piomelli and Greengard, 1990), and activation of oxidases
(Simonian and Coyle, 1996) all lead to the production of ROS.
The brain is more susceptible to oxidative damage than other organs.
Brain tissue is characterized by high oxygen consumption, high content of
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polyunsaturated lipids, accumulation of iron in certain brain regions, and
relatively low catalase activity. All these features make the brain susceptible
to oxidative injury (Halliwell, 1989). Oxidative stress occurring in
neurodegenerative disorders shows remarkable cellular selectivity (Simonian
and Coyle, 1996). Astrocytes maintain relatively high intracellular
concentration of GSH and recycle ascorbate, which make astrocytes more
resistant to oxidative damage than neurons and oligodendrocytes (Wilson,
1997; Peuchen, et.al., 1997). In addition, the neuroprotective effect of
astrocytes may partially prevent neurons from oxidative damage (Wilson,
1997).
In contrast to the brain, the liver contains higher levels of the metabolic
enzymes that generate ROS during mixed-function oxidation. However, the
liver also has a much stronger antioxidative defense, including higher levels
of glutathione and glutathione peroxidase (Makar, et.al., 1994).
Glutamate and Glutamate Homeostasis:
Glutamate is the major excitatory neurotransmitter in the central
nervous system (CNS). Glutamatergic transmission is involved in several
important brain frmctions, such as learning and memory (Bliss and
Collingridge, 1993). However, at elevated extracellular concentrations.
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glutamate can produce neuronal damage, a phenomenon know as
excitotoxicity (Choi, 1992). Several neurodegenerative diseases, including
stroke, epilepsy, Huntington's Disease, Amyotrophic Lateral Sclerosis (ALS),
and Alzheimer’s Disease, are potentially linked to glutamatergic
excitotoxicity (Gegelashvili and Schousboe, 1997).
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G lu U m atc

IC W w f
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■■

Figure 3. Schematic model for glutamate regulation. NM D A, NM DA receptor; AMPA,
AMPA receptor; KA, KA receptor; ACPD-G, G-protein coupled-AMPA receptor; PLC,
phospholipase C. (NichoUs and Attwell, 1990)

Glutamate is distributed throughout the entire central nervous system
(Monaghan, et.al., 1989). This amino acid neurotransmitter is packaged in
synaptic vesicles within glutamatergic presynaptic terminals and released into

14
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

the synaptic cleft upon stimulation (Nicholls and Attwell, 1990). After
release, glutamate activates receptors on pre- and postsynaptic neuronal and
glial membranes. Excitatory transmission and complex signaling processes,
such as long term potentiation (LTP), long term depression (LTD), and
neuronal plasticity are evoked through the activation of glutamatergic
ionotropic and metabotropic receptors (Cotman, et.al., 1989; Collingridge and
Wolf, 1991). The amount of glutamate in the synaptic cleft is less than 1 pM
in resting conditions, while the value can transiently reach 10'^ M when
glutamate release is stimulated (Fonnum, 1984; Nicholls and Attwell, 1990).
The glutamate in extracellular space is rapidly transported into astrocytes and
presynaptic neurons by glutamate transporters located in neurons and glia.
This action terminates glutamate synaptic transmission and prevents the
extracellular glutamate concentration from reaching neurotoxic levels
(Nicholls and Attwell, 1990). Glutamate is metabolized to glutamine by
glutamine synthetase (GS) , an astrocytic enzyme, via an ATP dependent
mechanism. Glutamine is transported from astrocytes back to neurons and
converted to glutamate by glutaminase in presynaptic neurons (Hamberger,
et.al., 1979). The synthesis, release, uptake, and metabolism of glutamate
constitute the glutamine cycle in CNS. Changes in the glutamine cycle, such
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as increased release of glutamate, loss of the glutamate transporter, or
inhibition of glutamine synthetase activity, may disrupt glutamate
homeostasis in the CNS, leading to elevated extracellular glutamate and
excitotoxicity (Bristol, and Rothstein, 1996; Trop, et.al., 1995). For example,
inhibition of GS by methionine sulfoximine triggers convulsant activity
(Rowe, et.al., 1969).
Growing evidence links oxidative stress and excitotoxic cell death
(Dykens, et.al, 1987). Both GS and glutamate transporters have been
reported to be inactivated by ROS in vivo and in vitro (Oliver, et.al., 1990;
Sorg, 1997). Free radicals can also increase the release of glutamate, leading
to increased glutamate in the synaptic cleft and prolonged glutamatergic
signals (Volterra, et.al., 1994). Following the activation of kainic acid (KA)
and N-methyl-D-aspartate (NMDA) receptors, the increase of intracellular
Ca^^ leads to the activation of nitric oxide synthetase, xanthine oxidase, and
release of arachidonic acid. These effects greatly increase the generation of
ROS (Lafon-Cazal, et.al, 1993; Sun, et.al., 1992). Oxidative damage to lipids
occurs following the activation of glutamate receptors (Puttfarcken, et.al.,
1993). In addition, antioxidants protect neurons against excitotoxic cell death
(Miyamoto, et.al., 1989)
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Loss of GS activity is generally considered as a sensitive indicator of
tissue oxidative injury (Oliver, et.al., 1990). The activity of GS, a key
enzyme regulating glutamate homeostasis and ammonia metabolism in the
CNS, decreases to 65% of control value after 2 hour reperfusion following 10
minutes ischemia. The reduction of GS activity is effectively prevented by
preadrnmistration of free radical spin trap reagents (Oliver, et.al., 1990).
Oxidative inactivation of GS involves the oxidation of His-269, Arg-344, and
unfolding of the peptide chain, which makes the enzyme susceptible to
proteases (Roseman and Levine, 1987).
Proposed Research:
Increased GYP lA l activity is associated with elevated generation of
ROS in 3-MC treated rats (Mishin, et.al., 1975), and induction of GYP lA l by
TGDD in hepatoma cells has been reported to cause oxidative DNA damage
(Park, et.al., 1996). All this evidence suggests that induction of GYP lA l
may increase oxidative stress in vivo. The presence of GYP lA l in the GNS
is well documented (Warner, et.al., 1991; Kohler, et.al, 1988). Investigation
of the interaction between GYP induction and oxidative damage in the brain is
a relatively new research area. Most research has been carried out on GYP
2E1, the enzyme induced by ethanol. However, the effect of ethanol on
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oxidative damage is complicated by increased ROS formation by mitochondria
(Kukielka, et.al., 1994) as well as metabolism of ethanol by various oxidases
(Montoliu, et.al., 1995). The regulatory effect of CYP 1A1 induction on
oxidative status of the brain has not been reported. In the present study, we
investigated whether induction of CYP 1A1 can cause oxidative damage to
lipids and proteins, and affect GS activity in the brain and liver. Although
acute exposure to PAHs and HAHs does not lead to neurotoxicity (IzdebskaSzymona, et.al, 1997; Unkila, et.al., 1995), the investigation of their ability to
cause or exacerbate oxidative damage may help to elucidate their role in other
CNS pathologies.
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Specific Objectives:
The overall goal of this project is to investigate the interaction between
CYP 1A1 induction and oxidative damage in the brain and liver. We
hypothesized that induction of CYP 1A1 following exposure to PAHs and
HAHs causes oxidative damage, and alters GS activity in the brain.
The following questions were addressed in the project:
1. Does 3-MC induce CYP lA l in rat brain and liver? Does the
dosing regimen affect the extent of CYP 1A1 induction in the brain and liver?
2. Does increased CYP 1A1 activity lead to more protein oxidation and
lipid peroxidation in rat brain and liver?
3. Does increased CYP lA l activity change the susceptibility of the
brain and liver to oxidative challenge?
4. Does induction of CYP 1A1 affect GS activity in rat brain and liver?
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Materials and Methods
Materials:
All chemicals were obtained either from Sigma (St. Louis, MO) or
from Fisher Scientific (Pittsburgh, PA) except 7-ethoxyresorufin (Biomol,
Plymouth, PA) and protein assay dye reagent (Bio-Rad, Hercules, CA).
Animal Treatment:
Male Sprague-Dawley rats (150-200 g) were purchased from Simonsen
Labs (Gilroy, CA). Rats were maintained on a 12 hour light-dark cycle with
food and water ad libitum. Rats were allowed to adjust from shipping for 45 days prior to beginning of experiments. 3-MC was suspended in com oil at
a concentration of 55 jumol/ml. Com oil or 3-MC was administered to rats
using two different schemes;
1. Five daily intraperitoneal injections of 110 pmol/Kg 3-MC or 2
ml/kg com oil (Dhawan, et.al, 1990).
2. A single intraperitoneal injection of 550 pmol/Kg 3-MC or 10 ml/Kg
com oil.
The rats were sacrificed one day, three days, five days, and ten days
after the last injection, n = 6-12 for each treatment.
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Microsomal Protein Preparation:
The rats were decapitated and the whole rat brain and tissues from the
biggest lobe of liver were quickly removed and rinsed in homogenization
buffer (150 mM NaCl, 67 mM Na 2 HP0 4 , 1 mM EDTA, 0.1 mM PMSF and
20% glycerol, pH = 7.4). One hemisphere of the brain and half of the liver
tissue were quickly frozen in a dry ice-ethanol bath and stored at -80 °C. The
other half of the tissues were used for brain and liver microsomal protein
preparation.
Rat brain and liver microsomes were prepared as described by Zhang
(1997). The brain and liver tissues were minced in approximately 15 ml of
homogenization buffer and homogenized by 10-12 strokes using a 15 ml
Wheateon Glass/Glass homogenizer and a Teflon pestle. Tissue
homogenates were centrifuged at 2000 x g for 10 minutes to remove cell
debris, followed by centrifugation of the supernatants at 10,000 x g for 20
minutes to remove mitochondria and nuclei. The supernatants were
centrifuged at 110,000 x g in an ultra-centrifuge for 60 minutes. All
centrifugations were carried out at 4 °C. The resulting supernatants were
saved and stored at -80 °C for glutamine synthetase activity assay. The
pellets were suspended in 800 pi of microsomal suspension buffer (67 mM
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N32HP04, 1 mM EDTA, 0.1 mM pepstatin, 0.1 mM leupeptin, 0.1 mM
PMSF and 20% glycerol, pH = 7.4) and transferred to a 1 ml glass
homogenizer. After 6-7 strokes for homogenization, the microsomal protein
suspensions were stored at -80 °C for no more than 30 days before assaying
for CYP lA l activity.
CYP lA l Activity Assay:
The CYP 1A1 activity in rat brain and liver microsomal proteins were
quantified by the ethoxyresorufm-O-deethylase (EROD) method as described
by Unkila with minor changes (Unkila, et.al., 1993). Aliquots (0.2 mg protein
for brain microsomes and 0.04 mg protein for liver microsomes) of the
microsomal suspensions in 67 mM sodium phosphate buffer (total volume 1
ml) were kept on ice. After the addition of 10 pi of 0.5 pM ethoxyresorufin
ethanol solution, the mixtures were transferred to a semimicro polystyrene
cuvette and incubated for 10 minutes at 37 °C. The assay was initiated by
adding 20 pi 50 mM NADPH. The reaction mixtures were incubated at 37
°C for 15 minutes for brain microsomes and 10 minutes for liver microsomes.
Resulting fluorescence was measured at 585 nm with excitation at 550 nm
using an Hitach F2000 fluorescence spectrophotometer. Non-specific
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fluorescence for the samples was measured using boiled, denatured samples
following the same protocol.
The amount of resorufin produced in the tissue homogenate
suspensions was calculated based on a standard curve developed from a
range of resorufin concentration in the presence of 5 pM ethoxyresorufin and
1 mM NADPH. Standards ranged from 0-15 nM for brain microsomes, 0-3
pM for 3-MC treated rat liver microsomes, and 0-50 nM resorufin for com oil
treated rat liver microsomes.
To confirm the assay condition, EROD assay was also carried out after
incubating some brain or liver microsomes at 37 °C with 50 pM a-NF, a
potent CYP 1A1 inhibitor, for ten minutes.
The time-course relationship for CYP 1A1 activity in rat brain and liver
was established for both schemes. The 3-MC-treated rats with maximum
CYP 1A1 activity in the brain or liver and the corresponding com oil-treated
controls were further used for lipid peroxidation and protein oxidation assays.
Lipid Peroxidation Assay:
The level of lipid peroxidation in rat brain and liver was quantified by
the thiobarbituric acid method (Buege, et.al., 1978). Frozen rat brain and
liver tissues prepared as previously described were thawed at room
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liver tissues prepared as previously described were thawed at room
temperature. The tissues were cut into small pieces and rinsed twice with 5
ml 67 mM sodium phosphate buffer (pH = 7.4). The tissues were
homogenized for 8-10 stokes in about 5 ml homogenization buffer at 4 '’C.
Aliquots (1.5 mg protein) of tissue homogenates were mixed with 0.05 M
Tris-HCl buffer (pH = 7.4) to a final volume of 1.5 ml. The reaction were
allowed to proceed at 37 °C for 10 minutes. Aliquots (1.5 ml) of TCA-TBAHCl reagent (15% w/v trichloroacetic acid, 0.375% w/v thiobarbituric acid
and 0.25 M HCl) were then added into test tubes on ice. The reaction
mixtures were vortexed vigorously and moved to an 80 °C water bath for 15
minutes. After stopping the reaction on ice, the reaction mixtures were
centrifuged at 3000 rpm for 5 minutes to remove the flocculent precipitate.
The absorbance of the supernatant was measured at 535 nm using a Beckman
DU650 spectrophotometer. Absorbance was corrected by a blank, which
contained all the reagents except the tissue homogenates.
The amount of thiobarbituric acid-reactive substance (TBARS) in
tissue homogenates was determined by comparison with a standard curve of a
range of MDA concentrations from 0-5 nM. MDA standard was prepared by
hydrolyzing malonaldehyde bis [dimethyl acetal] in 0.05 M Tris-HCl buffer.
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Protein Oxidation Assay:
Protein oxidation in rat brain and liver was quantified by the loss of
tryptophan fluorescence as described by Davies (Davies and Lin, 1987).
Aliquots of tissue homogenates (0.7 mg protein) in 67 mM sodium phosphate
buffer (total volume 1.5 ml) were mixed with 100 pi 20% sodium dodecyl
sulfate (SDS) and incubated at 37 °C for 30 minutes. Fluorescence for
tryptophan in the samples was measured at 340 nm with excitation at 280 nm
using an Hitach F2000 fluorescence spectrophotometer.
The effect of 3-MC treatment on protein oxidation was determined by
comparing tryptophan fluorescence between com oil-treated and 3-MCtreated rats.
Oxidative Challenge:
The brain and liver homogenates (1.5 mg protein), prepared as
described in the lipid peroxidation assay, were incubated at 37 °C for 10
minutes. Ten microliters of 15 mM NADPH, 10 pi of 15 mM FeCls, and 50
pi of 51 mM ADP were added to tissue homogenates and incubated at 37 °C
for 10 more minutes. The amounts of MDA generated was examined by
reacting with thiobarbituric acid as described in the lipid peroxidation assay.
In order to examine the effect of CYP lA l on lipid peroxidation under
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oxidative challenge, a-NF (50 luM) was incubated with tissue homogenates
for ten minutes before oxidative challenge.
Protein oxidation was also investigated by measuring tryptophan
fluorescence after oxidative challenge. Brain and liver homogenates (0.7 mg
protein) in 67 mM sodium phosphate buffer (total volume 1.5 ml) were first
incubated with 100 pi of 20% sodium dodecyl sulfate (SDS) at 37 °C for 20
minutes. Then 10 pi of 15 mM NADPH, 10 pi of 15 mM FeCb, and 50 pi of
51 mM ADP were added to tissue homogenates and incubated at 37 °C for 10
more minutes. Tryptophan fluorescence was measured as previously
described.
Glutamine Synthetase Assay:
Glutamine synthetase activity was determined by the method of
Meister (1985). The supernatants from the 110,000 x g centrifugation in the
microsomal preparation were used to determine GS activity. Aliquots (0.4 mg
protein) of the supernatants were added to 750 pi of a solution containing 0.1
M L-glutamine, 0.125 M hydroxylamine, 0.4 mM manganese chloride, 20
mM arsenic acid and 0.8 mM ADP. Sufficient volume of 67 mM sodium
phosphate buffer (pH=7.4) was added to make the final volume 1.5 ml.. The
reaction was carried out at 37 °C for 60 minutes. The reaction was stopped
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by removing the samples to an ice bath and adding 1.5 ml of 0.37 M ferric
chloride. After allowing 30 minutes for color development, samples were
centrifuged at 3000 rpm for 5 minutes to remove any debris. The absorbance
at 555 nm for the supernatants was read on a Beckman DU 650
spectrophotometer.
The amount of y-glutamyl hydroxymate (g-GH) produced was
determined by comparison with a standard curve of a range of g-GH
concentrations from 0-0.8 pM.
Protein Assay:
The protein content in samples were determined by the Bradford
method (Bradford, 1976). Samples and protein standards were reacted with
four-fold diluted protein assay dye reagent for 10 minutes at room
temperature. The absorbance for the reaction mixtures was measured at 595
nm by a Beckman DU650 spectrophotometer.
Statistical Analysis:
Statistical analysis was carried out using the GBSTAT ®program.
Treatment means were compared using ANOVA and the Newman-Keuls test.
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Results:
Identifîcatioi» of CYP lA l Reaction Conditions:
Preliminary studies were performed to optimize the EROD assay
conditions. Table 1 shows that the highest CYP lA l activity after 10 minutes
of incubation was observed with 0.2 mg of brain and 0,04 mg of liver
microsomal protein. Using these established amounts of protein, the reaction
was allowed to proceed 2-30 minutes. Maximum CYP 1A1 activity occurred
at 15 minutes in brain microsomes and 10 minutes in liver microsomes (Table
2). Therefore, 0.2 mg protein and 15 minutes reaction time were used in
EROD assays for brain microsomes, and 0.04 mg protein and 10 minutes
reaction time with liver microsomes.
Multiple Injection Protocol:
The induction of CYP lA l in rat brain and liver by 5 daily injections of
3-MC are shown in Figure 4 and Figure 5. Three days after the last dose, 3MC induced approximately a 7-fold increase in brain CYP lA l activity.
CYP lA l activity was 1.092 ±0.155 pmol resorufin/min/mg protein
following 3-MC treatment and 0.173 ± 0.06 pmol resorufin/min/mg protein in
com oil controls. No significant CYP lA l induction occurred one day, five
days, or ten days after multiple doses of 3-MC in rat brain. In contrast, CYP

28
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

lA l activity was increased in 3-MC treated rat liver one day after the
treatment. 3-MC treatment increased CYP lA l activity about 60-100 fold at
all time points. The increased enzyme activity in the brain and liver was
effectively inhibited by 50 pM a-NF, a selective CYP lA l inhibitor (Table
3).
Figures 6 and 7 show the amount of lipid peroxidation in rat brain and
liver following 3-MC treatment, and the additional thiobarbituric acid-reactive
substances (TBARS) generation following oxidative challenge. Three days
after dosing, the time when maximum CYP lA l activity was observed in both
brain and liver, 3-MC treatment did not change the amount of lipid
peroxidation in either tissue. The rate of TBARS generation was 0.27-0.3
nmol/min/mg protein in the brain and 0.16-0.21 nmol/min/mg protein in the
liver. 3-MC treatment did not increase lipid peroxidaton over that seen with
com oil-treated rats. In rat brain, oxidative challenge significantly increased
the levels of lipid peroxidation in 3-MC and com oil-treated rats. However,
this increase was not inhibited by 50 pM a-NF in either case. In rat liver, the
level of lipid peroxidation did not increase following oxidative challenge and
the addition of 50 pM a-NF did not change the rate of TBARS generation
after oxidative challenge.
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Figure 8 shows the extent of protein oxidation in rat brain and liver 3
days after 3-MC and com oil treatment. The loss of tryptophan fluorescence
in tissue homogenates serves as a marker for protein oxidation. 3-MC did not
increase brain protein oxidation. 3-MC treatment produced a 7.7% decrease
in tryptophan fluorescence in rat liver protein. The tryptophan fluorescence is
115 ± 0.787 in 3-MC-treated rats, which is significantly lower than the 125 ±
2. 62 value of com oil-treated rats.
Figures 9 and 10 show the effect of 3-MC treatment on GS activity in
the brain and liver. Neither brain nor liver GS activity was changed following
the induction of CYP lA l by multiple injections of 3-MC. Average GS
activity was 28-40 nmol/min/mg protein in rat brain, and 6-9 nmol/min/mg
protein in rat liver in both 3-MC and com oil groups.
Single Dose Protocol:
A single dose of 3-MC did not increase CYP lA l activity in rat brain
at any measured time point. The brain CYP lA l activity was almost
unmeasurable in most rats. Conversely, 3-MC caused a marked induction of
CYP lA l in rat liver. A 55-75 fold increase in CYP lA l activity was
observed one day, three days, five days, and ten days after treatment (Fig.
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11). CYP lA l activity was relatively close to the corresponding values in the
multiple injection protocol.
Figure 12 and figure 13 present data showing that a single injection of
3-MC did not increase lipid peroxidation in rat brain and liver. A single dose
of 3-MC produced similar levels and a similar pattern of lipid peroxidation as
that seen with rats receiving multiple doses of 3-MC.
The effect of a single dose of 3-MC on protein oxidation was
investigated in the brain and liver (Fig. 14). 3-MC exposure did not increase
protein oxidation in rat brain five days after treatment, while significantly
decrease liver tryptophan fluorescence to 91.6% of the value seen with com
oil-treated rats.
Oxidative challenge significantly oxidized brain protein (Fig. 15). The
tryptophan fluorescence markedly decreased from 166.8 ± 1.84 to 28.3 ±
1.24 following exposure to ADP, iron, and NADPH.
GS activity in rat brain and liver was not altered by 3-MC treatment at
any time point (Fig. 16, Fig. 17). The values of 23-30 nmol/min/mg protein
and 6-7 nmol/min/mg protein for the brain and liver GS activity respectively,
were in the same range as the values from the first treatment protocol.
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Table 1. Effect of Protein Content on CYP lA l Activity:
Microsomes Protein

(mg)
Brain

0.2
0.4

Reaction Time
CYP lA l Activity
(min)
(pmol resorufin/min/mg protein)
10
10

1.32 + 0.22
** 0.83 ±0.16
(nmol resorufin/min/mg protein)

Liver

0.04
0.08

10
10

4.73 ± 0.45
3.87 + 0.38

** = Significantly different from the CYP lA l activity measured at 0.2 mg
protein (P < 0.05).
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Table 2. Effect of Reaction Time on CYP lA l Activity.
Microsomes Protein
(mg)
Brain

0.2
0.2
0.2
0.2
0.2

Reaction Time
(min)

CYP lA l Activity
(pmol resorufin/min/mg protein)
** 0
* 0.98 ±0.26
1.13 ±0.30
1.32 ±0.22
* 0.96 ±0.11

2
5
10
15
30

(nmol resorufin/min/mg protein)
Liver

0.04
0.04
0.04
0.04
0.04

2
5
10
15
30

** 2.40 ± 0.34
3.72 ±0.83
4.72 ± 0.46
4.20 ± 0.29
* 3.06 ±0.15

* = CYP lA l activity is significantly different from the highest value (* P <
0.05, **P <0.01)
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Figure 4. Effect of 5 daily injections of 3-MC on CYP 1A1 activity in
rat brain. CYP lA l activity in rat brain was determined 1 day, 3 days, 5
days, and 10 days after 3-MC treatment. CYP lA l activity was expressed as
pmol resorufin generated/min/mg protein. Each data point represents mean ±
SEM (n = 6-12). ** = CYP lA l activity significantly increased over
corresponding values from com oil-treated rats (P < 0.01).
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Figure 5, Effect of 5 daily injections of 3-MC on CYPlAl activity in
rat liver. CYP 1A1 activity in rat liver was determined 1 day, 3 days, 5 days,
and 10 days after 3-MC treatment. CYP lA l activity was expressed as nmol
resorufin generated/min/mg protein. Each data point represents mean ± SEM
(n = 6-12). ** = CYP lA l activity significantly increased over corresponding
values from com oil-treated rats. # #= CYP lA l activity is significantly
higher than any other time point (P < 0.01).
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T ab le 3. Effect of a-N F on CYP lA l Activity.

Microsomes

Brain

Protein
(mg)

a-NF
(pM)

0.2
0.2

0
50

CYP lA l Activity
(pmol resorufin/min/mg protein)
1.09 + 0.15
** Q
(nmol resorufin/min/mg protein)

Liver

0.04
0.04

0
50

4.70 + 0.32
** 0.054 ± 0.003

** = The CYP lA l activity is significantly different than that seen without aN F(P<0.01).
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Figure 6. Lipid peroxidation in 3-MC and com oil treated rat brain.
The amount of lipid peroxidation in 3-MC and com oil treated rats brain was
evaluated 3 days after multiple injections, and expressed as nmol
TBARS/min/mg protein. CONT = extent of lipid peroxidation without
oxidative challenge. OX = lipid peroxidation following oxidative challenge.
OX + aNF = lipid peroxidation in the brain after treating with oxidative
challenge and a-NF. Each data point represents mean ± SEM (n=6-7). ** =
The amount of lipid peroxidation significantly increased over corresponding
CONT value (P < 0.01).
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Figure 7. Lipid peroxidation in 3-MC and com oil treated rat liver.
Lipid peroxidation was examined in 3-MC and com oil treated rat liver 3
days after multiple injections. The amount of lipid peroxidation was shown
as nmol TBARS/min/mg protein. Assay conditions were the same as in Fig. 6.
Each data point represents mean ± SEM (n=6-7).
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Figure 8. Protein oxidation in 3-MC and com oil-treated rat brain and
liver. Protein oxidation was examined in the brain and liver 3 days after
treatment. The amount of protein oxidation were determined by the loss of
tryptophan fluorescence at 345 nm. Each data point represents mean ± SEM
(n=6-7). * = The level of tryptophan fluorescence significantly different from
com oil group (* P < 0.05).
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Figure 9. GS activity in 3-MC and com oil-treated rat brain. OS
activity in rat brain was determined 1 day, 3 days, 5 days, and 10 days after 5
doses of 3-MC or com oil. GS activity is expressed as nmol y-glutamyl
hydroxymate (g-GH) generated /min/mg protein. Each data point represents
mean ± SEM (n=6-7).
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Figure 10. GS activity in 3-MC and com oil treated rat liver. GS
activity in rat liver was determined 1 day, 3 days, 5 days, and 10 days after 5
doses of 3-MC or com oil. GS activity is expressed as nmol y-glutamyl
hydroxymate (g-GH) generated/min/mg protein. Each data point represents
mean ± SEM (n=6-7).
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Figure 11. Effect of a single dose of 3-MC on GYP lA l activity in rat
liver. GYP lA l activity in rat liver was determined 1 day, 3 days, 5 days,
and 10 days after the injection. GYP lA l activity was expressed as nmol
resonifin generated/min/mg protein. Each data point represents mean ± SEM
(n = 6). ** = GYP lA l activity significantly increased over corresponding
values from com oil-treated rats (P < 0.01).
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Figure 12. Lipid peroxidation in 3-MC and com oil treated rat brain.
Lipid peroxidation was evaluated in rat brain 5 days after the single injection.
The amount of lipid peroxidation was expressed as nmol TBARS/min/mg
protein. CONT = extent of lipid peroxidation without oxidative challenge. OX
= lipid peroxidation following oxidative challenge. OX + aNF = lipid
peroxidation in the brain after treating with oxidative challenge and a-NF.
Each data point represents mean ± SEM (n=6). ** = The amount of lipid
peroxidation significantly increased over corresponding CONT value (P <
0 .01).
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Figure 13. Lipid peroxidation in 3-MC and com oil treated rat liver.
Lipid peroxidation was examined in rat liver 5 days after the single injection.
The amount of lipid peroxidation was expressed as nmol TBARS/min/mg
protein. Assay condition were same as in Fig. 12. Each data point represents
mean ± SEM (n=6).
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Figure 14. Protein oxidation in 3-MC and com oil treated rat liver.
Protein oxidation was examined in the brain and liver 5 days after a single
injection of 3-MC. The amount of protein oxidation were determined by loss
of tryptophan fluorescence at 345 nm. Each data point represents mean ±
SEM (n=6). ** = The level of tryptophan fluorescence significantly different
from com oil (P < 0.01).
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Figure 15. Effect of oxidative challenge on protein oxidation. The
extent of protein oxidation in rat brain was examined following oxidative
challenge. Each data point represents mean ± SEM (n=4-6). ** = Protein
oxidation was significantly increased by oxidative challenge (P < 0.01).
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Figure 16. GS activity in 3-MC and com oil treated rat brain. GS
activity in rat brain was determined 1 day, 3 days, 5 days, and 10 days after a
single dose of 3-MC or com oil. GS activity is expressed as nmol y-glutamyl
hydroxymate (g-GH) generated/min/mg protein. Each data point represents
mean ± SEM (n=6).
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Figure 17. GS activity in 3-MC and com oil treated rat liver. GS
activity in rat liver was determined 1 day, 3 days, 5 days, and 10 days after a
single dose of 3-MC or com oil. GS activity is expressed as nmol y-glutamyl
hydroxymate (g-GH) generated/min/mg protein. Each data point represents
mean ± SEM (n=6).
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Discussion
Two well established protocols were used to induce CYP 1A1 in the
brain and liver. Both protocols exposed rats to a total of 550 pmol/kg of 3MC. Although this dose is much larger than the estimated environmental
exposure to PAHs and HAHs (nmol/Kg - pmol/Kg) (McFarland and Clarke,
1989), it is in the same range as the doses that were used in other studies to
produce significant increases in CYP lA l activity in the rat brain and liver
(Dhawan, et.al., 1990; Suarez, et.al., 1975).
CYP lA l activity in the brain and liver was examined one day, three
days, five days, and ten days after 3-MC treatment (see Figs. 4, 5, and 11).
In order to test whether the dosing regimen affected CYP lA l induction and
the extent of oxidative damage in tissues, 3-MC (550 pmol/Kg) was
administered to rats either by five daily injections or a single injection.
Induction of CYP lA l in the brain and liver had different time-course
relationships after these two injection protocols. A significant increase in
CYP lA l activity in rat brain was detected three days after five daily
injections of 3-MC, while brain CYP lA l activity did not increase at all time
points after a single dose of 3-MC. Three days after 5 daily injections of 3MC, rat brain CYP lA l activity was 1.092 ±0.155 pmol/min/mg protein in
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our study, which is similar to 1.44 ±0.5 pmol/min/mg protein reported by
Perrin, et.al. (1990). Dramatically increased CYP lA l activity was observed
in rat liver at all time points after both protocols. The extent of hepatic
enzyme induction produced by the single injection protocol was less than that
seen three days after the multiple injection protocol.
The responses of the brain and liver to 3-MC treatment were
remarkably different. A relatively transient increase in CYP lA l activity in
the brain was in contrast to much more persistent induction of CYP 1A1 in
the liver. 3-MC treatment increased CYP 1A1 activity seven fold in the rat
brain, which is much lower than the 50-100 fold increase of CYP lA l
activity in the liver. At all time points after both injection protocols, CYP
lA l activity ranged from 0-0.173 pmol/min/mg protein and 30-45
pmol/min/mg protein in the control rat brain and liver, respectively. These
data are slightly lower than 0.45-0.55 pmol/min/mg protein and 60
pmol/min/mg protein reported by Perrin, et.al. (1990), using a slightly
different injection protocol (0.5 ml com oil for 3 days).
Neither treatment protocol led to a sustained increase in CYP 1A1
activity in the brain. One possible explanation for the short duration of CYP
induction in the brain is that CYP 1A1 can be destroyed during lipid
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peroxidation (Bast and Haenen, 1984), Another possible explanation is that
the metabolism of 3-MC may be accelerated by increased CYP lA l activity.
Although we did not observe increased CYP lA l activity in the brain after a
single dose of 3-MC, it is still possible that the induction of CYP lA l
occurred at a time that was not chosen in our protocol. Also, when
comparing the results of the two protocols in the liver, the multiple dose
regimen induced more CYP lA l activity. Thus it is possible that the single
dose protocol was not sufficiently rigorous to induce CYP lA l in the brain.
Adthough the brain is particularly vulnerable to lipid peroxidation,
TEARS generation did not change following increased CYP lA l activity (see
Fig. 6). Our finding implies that endogenous antioxidant defense can protect
the brain from ROS attack of the magnitude that can be generated by
induction of CYP lAl. Another possible reason for the lack of increase in
lipid peroxidation is that 3-MC treatment may enhance antioxidant defenses
by changing the levels of antioxidants. For example, 3-MC transcriptionally
induces glutathione S-transferase (GST) via AhR (Okey, et.al, 1994).
Increased GST enhances the secretion of 3-MC metabolites, inhibits lipid
peroxidation by favoring the reduction of lipid hydroperoxides to stable lipid
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aldehydes, and protects against lipid peroxidation by enhancing the secretion
of cytotoxic aldehyde products (Nordmann, 1994).
Induction of another CYP isoform is linked with oxidative challenges
in rat brain. Montoliu, et.al. (1994) demonstrated that rats exposed to ethanol
for 14 days exhibited induction of CYP 2E1, increased ROS formation, and
depletion of GSH in the brain. The increased formation of ROS after ethanol
treatment can be partially inhibited in vitro by CYP 2E1 antibody. However,
chronic alcohol consumption did not enhance the production of TEARS.
Conversely, later studies by Montoliu, et.al. (1995) demonstrated that
fourteen day exposure to 25 mM or 50 mM ethanol induced CYP 2E1 and
increased lipid peroxidation in astrocytes. However, this study did not
address the role of oxidases other than CYP 2E1 in ethanol metabolism.
In spite of large increases in CYP lA l activity, neither 5 daily
injections nor a single dose of 3-MC caused measurable lipid peroxidation in
the rat liver (see Figs. 7, 13). In our studies, the level of TEARS in the com
oil-treated rat liver is similar to the value 0.02-0.04 nmol/min/mg protein
detected by Iba (1988) in rat liver three days after receiving three daily
injections of 0.4 ml of com oil. Our result is consistent with previous studies
showing that treatment with 150 pmol/Kg 3-MC for two days did not produce
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lipid peroxidation in rat liver (Suarez, et.al., 1975; Junqueira, et.al., 1991).
Both results suggest that the hepatic antioxidant defense can effectively
scavenge oxygen radicals generated by increased CYP lAl. Induction of
glutathione S-transferase (GST) by 3-MC in the liver may also play a role in
preventing oxidative damage in the liver.
The minor involvement of CYP 1A1 in lipid peroxidation was
confirmed by assessing its ability to promote lipid peroxidation following
oxidative challenge (see Figs. 6, 7, 13). The extent of lipid peroxidation was
examined after challenging the brain and liver homogenates with ferric
chloride, ADP, and NADPH, an oxidative challenge system shown by
Svingen to significantly increase CYP-mediated lipid peroxidation in
microsomes (Svingen, et.al., 1979). In this oxidative challenge system,
NADPH promotes CYP lA l activity, ferric chloride catalyzes the generation
of hydroxyl radicals from H2 O2 , and facilitates the decomposition of lipid
hydroperoxides to peroxyl and alkoxyl radicals (Reiter, 1995). ADP
enhances the electron outflow from mitochondria (Simonian and Coyle,
1996). In our study, oxidative challenge dramatically increased the extent of
lipid peroxidation in the brain, while no change was seen in the liver. CYP
lA l induction by 3-MC did not lead to more lipid peroxidation in either the

53
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

brain or liver. The effect of oxidative challenge on lipid peroxidation could
not be inhibited by 50 pM a-NF, a potent CYP 1A1 inhibitor. These results
indicate that induction of CYP lA l following 3-MC treatment did not
exacerbate lipid peroxidation in the brain and liver under oxidative stress,
implying that CYP 1A1 induction can not alter the outcome of oxidative
stress associated with CNS or hepatic diseases.
Protein oxidation was measured by tryptophan fluorescence method of
Teale (1959). Tryptophan fluorescence accounts for about 95% of the total
fluorescence at 345 nm induced by excitation at 280 nm (Teale, 1959).
Neither 3-MC injection protocol increased brain protein oxidation in our
study (see Figs. 8, 14). Increased CYP lA l activity in the brain following 3MC treatment did not change protein tryptophan fluorescence, suggesting
that, similar to lipids, the induction of CYP lA l does not produce measurable
brain protein oxidation.
In rat liver, both 3-MC-injection protocols decreased the protein
tryptophan fluorescence by 8-9% (see Fig. 8, 14). This small reduction was
in contrast to an 80 % decrease in tryptophan fluorescence following
oxidative challenge (see Fig. 15). Thus the 8-9% reduction in tryptophan
fluorescence dose not represent major oxidation of hepatic protein.
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Additional evidence that CYP lA l induction did not cause significant
protein oxidation was found by assessing GS activity. The enzyme activity
was not changed by either injection protocol in the rat brain and liver (see
Figs. 9, 10, 16, 17). Brain GS activity ranged from 25-40 nmol/min/mg
protein and liver GS from 6-9 nmol/min/mg protein in 3-MC and com oiltreated rats. These values are consistent with data from others studies, e.g.,
22-35 nmol/min/mg protein for brain GS, and 7-22 nmol/min/mg protein for
liver GS (Wong, et.al., 1980; Wong and Dunn, 1977). GS is very susceptible
to oxidative damage (Oliver, et.al., 1990) and oxidized GS is prone to
cleavage by proteases (Lee, et.al, 1988). However, in our study, elevated
CYP 1A1 activity in rat brain observed three days after multiple doses of 3MC did not affect brain GS. This result is in accordance with the previous
study by Bondy and Guo (1994). They reported that intraperitoneal injection
of 4.5 g/Kg ethanol did not change brain GS activity 2 hours and 18 hours
after treatment. Under the same conditions, ROS formation was increased
and GS activity was decreased in the liver.
GS is located in astrocytes in CNS, an environment with relatively high
antioxidant defenses. This may be an explanation for the stable GS activity in
the brain following 3-MC treatment. Astrocytes accumulate a-tocopherol
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and ascorbate, contain more glutathione, and exhibit higher GST activity than
neurons (Wilson, 1997). If more ROS are generated by increased CYP 1A1
activity, the greater antioxidant defense in astrocytes may prevent detectable
damage. In addition, the amount of ROS generated in astrocytes has not been
quantified. Although the minor induction of CYP in the brain may lead to
more ROS formation, we are unable to compare the increased generation of
ROS from CYP 1AI with more severe oxidative injury models that decrease
GS activity by 40 % (Oliver, et.al., 1990).
The rat liver showed extensive CYP lA l induction after 3-MC
treatment, which may significantly increase the formation of ROS. However,
neither multiple doses nor a single dose of 3-MC changed hepatic GS activity
in our study (see Figs. 10, 17). The levels of GSH, GSH-metabolizing
enzymes, and catalase are higher in the liver than in the brain (Kretzscgnar,
1996). ROS generated by CYP lA l may be effectively scavenged by these
antioxidants. Studies by Bondy and Guo (1994) showed that acute ethanol or
acetaldehyde treatment cause significant depression of GS in the rat liver.
Possible reasons for the difference seen with CYP 1A1 and CYP 2E1
induction include the generation of ROS during ethanol or acetaldehyde
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metabolism by various oxidases, as well as increased ROS formation from
mitochondria (Montoliu, et.al, 1995; Kukielka, et.al., 1994).
The lack of an effect of CYP lA l induction on brain GS activity
indicates that exposure to 3-MC does not alter this important component in
glutamate homeostasis. Moreover, the induction of a much higher level of
CYP 1A1 activity also failed to affect the much lower level of GS activity
found in liver. Although GS represents only one part of the glutamine cycle,
the lack of evidence that CYP lA l produces any oxidative damage makes it
unlikely that CYP 1A1 induction has any significant effect on glutamate
homeostasis. These observations also make it unlikely that environmental
exposure to inducers of CYP 1A1 can influence the excitotoxic component of
neurologic disorders.
In conclusion, this project explored potential links between PAH
exposure, oxidative damage, and glutamate homeostasis. Our studies
demonstrated that induction of CYP 1A1 following 3-MC treatment did not
oxidize either proteins or lipids, or affect GS activity in the rat brain and liver.
The dosing regimen of 3-MC affected the induction of CYP 1A1 in the brain
and liver, while no effect on the extent of oxidative damage was seen in either
tissue. Furthermore, increased CYP lA l activity did not change the extent of
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lipid peroxidation in the brain and liver following oxidative challenge. The
inability of 3-MC to depress brain GS suggests that induction of CYP 1A1
does not disrupt glutamate homeostasis through this important component. If
increased CYP lA l activity in the brain and liver following 3-MC treatment
leads to increased ROS formation, the increase is insufficient to overwhelm
the endogenous antioxidant defense system, produce detectable oxidative
damage, and alter glutamate homeostasis.
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